Big Rounds, Big Bucks For Biotechs In 2015
This article was originally published in Start Up
Gurnet Capital's $600 million commitment to Boston Pharmaceuticals Inc. caps what has been a banner year for huge private biotech financings. Boston Pharma's is the biggest private round of the year so far, but it has plenty of company.
You may also be interested in...
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)
We nominated 15 deals in three categories. You picked the winners.